Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. develops allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions using its AlloSCOPE cell differentiation and expansion platform. Its pipeline includes OpRegen, also known as RG6501, for geographic atrophy secondary to age-related macular degeneration; OPC1 for spinal cord injury; ReSonance, or ANP1, for hearing loss; and COR1 for corneal endothelial disease.
Recurring company news covers clinical data presentations, preclinical program launches, manufacturing and platform updates, research collaborations, milestone activity, financial results, business updates, and scientific governance. Updates frequently connect Lineage’s cell transplant programs with ophthalmology, neurology, auditory disease, and other non-oncology therapeutic areas.
Lineage Cell Therapeutics (LCTX) has expanded its cell therapy pipeline to include an investigational auditory neuronal cell transplant aimed at treating hearing loss, particularly auditory neuropathy spectrum disorders. The company has filed for intellectual property to support this initiative, which addresses a significant global health issue affecting over 430 million people. CEO Brian Culley highlighted the potential benefits of auditory neuronal transplants and emphasized the efficient development process using existing infrastructure. The initiative follows a recent partnership with Roche and Genentech worth up to $670 million.
Lineage Cell Therapeutics (LCTX) reported full results from a Phase 1/2a clinical study of RG6501 (OpRegen®) for dry age-related macular degeneration (AMD). The therapy is developed in collaboration with Roche and Genentech. Results will be presented at the 2022 ARVO Annual Meeting. The study involved 24 patients across four cohorts, assessing safety and efficacy. No new treatment emergent adverse events were reported, indicating OpRegen has been well tolerated. Currently, there are no FDA or EMA approved treatments for dry AMD, highlighting the potential for OpRegen in a significant market.
Lineage Cell Therapeutics (LCTX) announced an exclusive worldwide collaboration with Roche and Genentech for the development of OpRegen, a retinal cell therapy, valued at up to $670 million. This partnership underscores the validation of Lineage's technology platform. In Q4 2021, total revenues increased to $1.2 million from $0.4 million in 2020, primarily from royalties and licensing fees. However, operating expenses surged to $29.2 million due to OpRegen-related costs, leading to a net loss of $29 million for the quarter. Lineage held $55.7 million in cash and equivalents as of December 31, 2021.
Lineage Cell Therapeutics, Inc. (LCTX) will release its Q4 and full-year 2021 financial results on March 10, 2022, after market close. A conference call will be held on the same day at 4:30 PM ET to discuss these results and provide a business update. LCTX focuses on developing allogeneic cell therapies targeting unmet medical needs, including treatments for age-related macular degeneration and spinal cord injuries. Investors can access the call by phone or via a live webcast on the company’s website.
Lineage Cell Therapeutics (AMEX: LCTX) announced that CEO Brian M. Culley will present at the B. Riley Securities 2022 Virtual Oncology Conference at 2:00 PM Eastern. The presentation will cover updates on the cell therapy pipeline, including clinical development plans for OPC1 and VAC2. Recently, Lineage received a $50 million upfront payment from Genentech for its OpRegen program.
Lineage Cell Therapeutics (LCTX), a clinical-stage biotechnology firm, announced that CEO Brian M. Culley will present at the H.C. Wainwright Bioconnect Virtual Conference. The presentation will be available on demand starting January 10, 2022, at 7:00 AM ET on the company's website. Lineage focuses on developing innovative cell therapies for unmet medical needs, including three leading candidates: OpRegen for dry age-related macular degeneration, OPC1 for acute spinal cord injuries, and VAC2 for non-small cell lung cancer.
Lineage Cell Therapeutics announced a $50 million upfront payment from Genentech as part of a collaboration for the development of OpRegen, a cell therapy targeting advanced dry AMD with GA. The total potential payment could reach $670 million, including milestone payments and royalties. Genentech will lead further clinical development, while Lineage will complete current studies and manufacturing tasks. This partnership aims to leverage Genentech's expertise to expedite OpRegen's clinical progress and commercialization.
Lineage Cell Therapeutics (LCTX) announced significant findings from its OpRegen Phase 1/2a clinical study, reporting retinal tissue restoration in four patients with dry age-related macular degeneration (AMD). The areas of geographic atrophy diminished or remained stable over 12 months, and all patients exhibited improvements in visual acuity. Statistically significant differences in visual acuity between treated and untreated eyes were observed at 9, 12, and 15 months. Lineage plans to engage with the FDA regarding OpRegen's development, which has been well tolerated without serious adverse events reported.
Lineage Cell Therapeutics reported positive interim results from its Phase 1/2a clinical trial of OpRegen, a therapy for dry age-related macular degeneration (AMD). Over 12 months, patients in Cohort 4 showed significant improvements in retinal restoration and visual acuity. Specifically, 58% of these patients maintained or improved their vision compared to 67% of untreated eyes. The treatment has been well tolerated, with no new adverse events reported. Lineage plans to engage with the FDA regarding future trials in early 2022.
Lineage Cell Therapeutics (LCTX) reported third quarter 2021 financials, highlighting ongoing clinical advancements in its OpRegen program for dry AMD. Key achievements include positive interim outcomes in 67% of treated patients and a new delivery device for OPC1 trials underway. The company holds $65.1 million in cash and marketable securities. Total revenues rose to $2.3 million, driven by a $1.6 million increase in royalty revenues. Operating expenses totaled $8.1 million. Despite a net loss of $7.8 million, the company is preparing for FDA engagement and clinical trials slated for Q4 2021 and Q1 2022.